Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab-Reference-Cited by-同舟云学术

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

Published:2023-07-17 Issue:5 Volume:12 Page:1709-1728
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Geiger Caroline K.,Sheinson Danny,To Tu My,Jones David,Bonine Nicole G.

Funder

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00523-3.pdf

Reference64 articles.

1. Whetten-Goldstein K, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419–25.

2. Bebo B, et al. The economic burden of multiple sclerosis in the United States. Estimate Direct Indirect Costs. 2022;98(18):e1810–7.

3. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639–47.

4. Wallin MT, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–40.

5. Yang JH, et al. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:1–20.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05

2. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study;Neurology International;2024-03-29

3. Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis;Drugs - Real World Outcomes;2023-09-21